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Abstract
Background: Head and neck squamous cell cancer (HNSCC) frequently causes severe symptoms that may be
reduced, when the tumor is successfully treated. The SOCCER trial studied the association of treatment response
with patient reported tumor symptom burden in first line treatment of recurrent and/or metastatic HNSCC.
Methods: In this prospective, multi-center, non-interventional trial patients were treated either with platinum-based
chemotherapy and cetuximab or radiotherapy and cetuximab. Tumor symptom burden was assessed every four
weeks with a questionnaire containing ten visual analogue scales (VAS, range 0–100), which were summarized to
the overall VAS score.
Results: Fourhundred seventy patients were registered in 97 German centers. A total of 315 patients with at least
the baseline and one subsequent questionnaire were available for analysis. Changes in the VAS score were rated as
absolute differences from baseline. Negative values indicate improvement of symptoms. The overall VAS score
improved significantly at the first post-baseline assessment in responders (− 2.13 vs. non-responders + 1.15, p =
0.048), and even more for the best post-baseline assessment (− 7.82 vs. non-responders − 1.97, p = 0.0005). The VAS
for pain (− 16.37 vs. non-responders − 8.89, p = 0.001) and swallowing of solid food (− 16.67 vs. non-responders −
5.06, p = 0.002) improved significantly more in responders (best post-baseline assessment). In the multivariable Cox
regression analysis, worse overall VAS scores were associated with worse overall survival (hazard ratio for death 1.12
per 10 points increment on the overall VAS scale, 95% CI 1.05–1.20, p = 0.0009).
Conclusion: In unselected patients beyond randomized controlled trials, treatment response lowers tumor
symptom burden in recurrent and/or metastatic HNSCC.
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Background
Patients with recurrent and/or metastatic head and neck
squamous cell carcinoma (HNSCC) still have a poor
prognosis. In the last decade many of these patients were
treated with palliative chemotherapy with platinum, 5-
flurouracil and cetuximab (EXTREME regimen) [1]. Sal-
vage surgery or re-irradiation is a treatment option for
selected patients with locoregional recurrences. Re-
irradiation can either be administered either alone or in
combination with chemotherapy or cetuximab [2, 3]. In
recent years immune checkpoint inhibitors targeting the
programmed cell death 1 protein (PD-1) / programmed
cell death ligand 1 (PD-L1) pathway have become a new
treatment option either alone or in combination with
chemotherapy [4]. Compared to other tumors, recurrent
and/or metastatic HNSCC patients frequently suffer
from severe tumor symptom burden such as swallowing
problems and pain [5]. In these patients, good palliative
treatment should not only focus on survival prolonga-
tion, but also to improve tumor symptoms and subse-
quently improve the patient’s quality of life.
In the SOCCER trial patients with recurrent and/or
metastatic HNSCC were treated either with chemother-
apy and cetuximab or radiotherapy and cetuximab. The
hypothesis of the trial was that this treatment will lead
to a better control of tumor-related symptom burden in
responding patients. The non-interventional trial
focused on the patients’ self-reported tumor symptom
burden in treatment responders compared to non-
responders. This may support the use of treatment
schemes with high response rates for patients with se-




Patients with recurrent and/or metastatic squamous cell
carcinoma of the oral cavity, oropharynx, hypopharynx
and larynx were eligible for this study. Key criteria for
eligibility were first line systemic treatment in the recur-
rent and/or metastatic situation and the willingness of
the patients to fill in the tumor symptoms questionnaire.
As the trial should represent unselected patients, there
were no limitations regarding baseline ECOG perform-
ance status or blood parameters. Tumor stages were
evaluated according to TNM 7th edition.
Trial design and treatments
In this prospective, multi-center, non-interventional
study, patients were treated either with platinum-based
chemotherapy in combination with cetuximab or radio-
therapy in combination with cetuximab. The treatment
with cetuximab was according to the European Medi-
cines Agency (EMA) marketing authorization.
Cetuximab was administered at an initial dose of 400 mg
per square meter body surface area, followed by subse-
quent doses of 250 mg per square meter body surface
area. In combination with radiotherapy, cetuximab treat-
ment started one week prior to radiotherapy and lasted
till the end of radiotherapy. In combination with
platinum-based chemotherapy, cetuximab was given
concomitantly with chemotherapy and continued as
maintenance therapy until disease progression. The allo-
cation to the treatment method was made by the treat-
ing physician.
Endpoints and assessments
The primary endpoint of the trial was the association be-
tween the patients’ tumor symptom burden and treat-
ment response. The patients’ tumor symptom burden
was studied using a 10 item containing questionnaire.
Patients filled in this questionnaire before and every
fourth week during treatment. The questionnaire in-
cluded self-evaluation of pain, breathing, swallowing
(solid, mashed, fluid), speech, smelling, taste, physical ac-
tivity and overall health state. The patients reported the
severity of problems on a visual analogue scale (VAS)
from 0 till 100 (supplementary Fig. S1). Higher values
represent heavier symptoms. The overall VAS score is
the average value of the 10 single VAS scores. The pa-
tients’ tumor symptom burden should be evaluated every
four weeks. For tumor response assessment, RECIST cri-
teria version 1.1 were recommended. There was no cen-
tral RECIST evaluation. Best overall response (BOR)
categories during treatment were determined for each
patient as: complete response (CR), partial response
(PR), stable disease (SD), progressive diseases (PD) and
not assessable (NA). The overall response rate (ORR)
was the proportion of patients with CR or PR and the
disease control rate (DCR) was the proportion of pa-
tients with CR, PR or SD. Secondary endpoints of the
trial included overall survival (OS) and progression-free
survival (PFS).
Trial oversight
The trial was registered with ClinicalTrials.gov (identi-
fier: NCT00122460). The institutional review board at
the Friedrich-Alexander-Universität Erlangen-Nürnberg
(number: 84_12 B) approved the non-interventional trial.
All patients gave written informed consent before enroll-
ment. The academic authors designed the trial in collab-
oration with the sponsor (Merck Serono GmbH).
Statistical analysis
Target Analysis Set (TAS) was defined as all registered
patients who fulfilled the eligibility criteria. The modified
TAS (mTAS) was defined as all patients in the TAS,
who had at least one evaluable pair of questionnaires
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before and during treatment. Analysis of covariance
(ANCOVA) were used to investigate the association be-
tween tumor response (CR/PR vs SD/PD/NA) and the
changes in VAS scores from baseline to three time
points (1) the first post-baseline assessment, (2) the best
post-baseline VAS value and (3) the VAS assessment at
treatment end. The baseline VAS values were considered
as covariates in the ANCOVA and Least Square Means
(LSM) including 95% confidence intervals (CI) were
determined.
The Wilson Score method was used to determine
95%CI for ORR and DCR rates. Kaplan-Meier estimates
were applied for all time-to-event variables (PFS and
OS) to estimates the survival probabilities at various
time points and the median survival time after start of
treatment.
Cox proportional hazard methods were used to inves-
tigate the association between various baseline factors
(including the overall VAS symptom score) and OS. A
backward selection procedure was applied considering
all factor with an effect p-value of < 0.2 in the univariate
analysis to identify independent prognostic factor for
OS. The p-value in the backward selection to remain in
the final model was 0.05. SAS version 9.3 was used to
perform the statistical analysis.
Results
Patients and treatment
Between October 2012 and June 2019 a total of 470 pa-
tients were registered in 97 German centers. Seventy-
nine patients were excluded as they violated at least one
eligibility criteria (Fig. 1). The most frequent eligibility
criteria violation was a missing combination of cetuxi-
mab with radiotherapy or platinum-based chemotherapy.
The remaining 391 patients were included in the TAS.
Seventy-six patients provided no evaluable pair of ques-
tionnaires before and during therapy, and thus in the
mTAS 315 patients were evaluable. Clinical characteris-
tics of the 391 TAS patients are given in Table 1. One
hundred ninety-eight patients presented with local re-
currence only (50.6%), 119 patients had distant metasta-
ses only (30%) and 74 patients (19%) had local relapse
and distant metastases. Seventy-seven patients with an
ECOG score of ≥2 were included (20%) and 124 patients
had a Charlson comorbidity score greater than one
(32%). Treatment consisted of cetuximab plus radiother-
apy in 78 patients (20%) and cetuximab plus chemother-
apy in 309 patients (79.0%), 4 patients received both
(1%). The chemotherapy was cisplatin based in 174 pa-
tients (56%) and carboplatin based in 139 patients (44%).
Two hundred sixty-four patients had received prior sur-
gery (68%) and 323 patients prior radiotherapy (83%).
Response to treatment
The mean follow-up time was 8.6 months (range: 0–
33.8). The ORR in the entire cohort was 33% (95%CI:
28.8–38.1) and DCR was 56% (95%CI: 51.3–61.1). In the
subgroup chemotherapy-cetuximab the ORR was 32%
and in the subgroup radiotherapy-cetuximab 39%. In
addition, Kaplan-Meier analyses of OS and PFS were
performed in the entire cohort (TAS cohort) (supple-
mentary Fig. S2). The median PFS was 5.5 months
(95%CI: 4.8–6.0) and the median OS was 9.5 months
(95%CI: 8.5–10.9).
Baseline symptom burden
Baseline symptoms of the 315 evaluable patients
(mTAS) are given in Fig. 2. The mean overall VAS
Fig. 1 Consort diagram. TAS: Target Analysis Set; mTAS: modified TAS; CT: Chemotherapy; RT: Radiotherapy; VAS: Visual Analogue Scale. *Some
patients violated more than one criterion
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Table 1 Patient characteristics
Patient characteristics (TAS cohort, N = 391)
Age at study inclusion [years], median (range) 62 (29–89)








Oral cavity 97 (25)
Other location 72 (18)
Prior therapy, n (%)
Radiotherapy 320 (82)
Surgery 264 (68)
Disease progression at study inclusion, n (%)
Local recurrence only 198 (51)
Distant metastases only 119 (30)
Local recurrence and distant metastases 74 (19)
Charlson Comorbidity Index at study inclusion, n (%)
0 188 (48)
1 79 (20)
> 1 124 (32)
ECOG performance status at treatment initiation, n (%)
0 65 (17)
1 225 (58)
≥ 2 77 (20)
Missing 24 (6)
Alcohol consumption, n (%)
Never 87 (22)
Several times per month 85 (22)
Several times per week or daily 101 (26)
Missing 118 (30)
Smoking habits, n (%)
Never smoked 102 (26)
Former smoker 148 (38)
Current smoker 140 (36)
Missing 1 (0)
Pack years, former and current smoker (n = 288), median (range) 35 (1–200)
Applied treatment regimen, n (%)
Radiotherapy + cetuximab 78 (20)
Chemotherapy + cetuximab 309 (79)
Radio-chemotherapy + cetuximab 4 (1)
Applied chemotherapy regimen (n = 313), n (%)
Cisplatin-based 174 (56)
Carboplatin-based 139 (44)
TAS Target Analysis Set, ECOG Eastern Cooperative Oncology Group. aMultiple locations per patient possible
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score before treatment was 35.4, slightly worse than
the mean score for pain with 31.3. Most severe symp-
toms at baseline were swallowing problems with solid
food (mean 57.7), followed by speech problems (mean
40.5), and restriction of physical activities (mean
38.3). The self-assessed mean actual overall heath
state was 46.1 and thus worse than most of the single
symptoms. In addition, baseline symptoms were ana-
lyzed separately in patients with locoregional recur-
rence only (without distant metastases) and in
patients with distant metastases (or both). Patients
with locoregional recurrence had worse baseline swal-
lowing fuction of solid/ mashed food and liquids and
more speech problems compared to patients with dis-
tant metastases (supplementary Fig. S3).
Correlation of treatment response and tumor symptoms
Changes in the patients’ symptom burden are studied
for responders (CR/PR) versus non-responders (SD, PD,
NA). All changes are displayed for the three time points:
The “first post-baseline” assessment compares the first
assessment during treatment with the baseline values.
The “best post-baseline” assessment compares the best
post baseline values of any questionnaire during treat-
ment with the baseline values. The “end of treatment”
assessment compares the values at treatment termin-
ation with the baseline values. Negative values indicate
improved symptoms and positive values deteriorated
symptoms.
The change of overall VAS score from baseline was
significantly better in responders compared to non-
responders at the first post-baseline assessment (LSM
responders − 2.13 vs. non-responders + 1.15, p = 0.0476)
(Fig. 3). This effect became stronger, when the best post-
baseline assessment was chosen (LSM responders − 7.82
vs. non-responders − 1.97, p = 0.0005). At end of therapy
the mean overall tumor symptom score returned to
baseline in responders and deteriorated in non-
responders (LSM responders + 0.78 vs. non-responders
+ 6.99, p = 0.0088).
An additional analysis of changes of the overall VAS
score in patients with locoregional recurrence only
(without distant metastases) and in patients with distant
metastases (or both) was performed. Changes of the
overall VAS score at the three time points “first post-
baseline assessment”, “best post-baseline assessment”
and “assessment at treatment end” were similar to the
changes in the entire cohort and did not differ in pa-
tients with locoregional recurrence and distant metasta-
ses (supplementary Fig. S4).
The results of the ten single symptom sub-VAS scores
are presented in Fig. 4. In the swallowing assessment, es-
pecially solid food was a problem for the patients. At the
best post-baseline assessment swallowing of solid food
improved significantly stronger in responders (LSM −
16.67 vs. non-responders − 5.06, p = 0.0016) (Fig. 4a).
For swallowing mashed or liquid food also significant
differences in favor of responders were observed at the
best post-baseline and the end of therapy assessment
(Fig. 4b, c). Larger differences were seen for the symp-
tom pain (Fig. 4d). At the best post-baseline assessment
the mean pain score has improved considerably more in
responders than in non-responders (LSM: responders −
16.37 vs. non-responders − 8.89, p = 0.0011). Similar to
swallowing problems, also restriction of smell or taste
both were significantly better in responders when the
best post-baseline assessment was compared (Fig. 4 e, f).
Also speech problems were a main impairment of
Fig. 2 Baseline symptom burden. Baseline symptom burden of the 315 mTAS patients. Values range from 0 to 100, higher values represent
heavier symptoms. The point ♦ in the box indicates the mean and the horizontal lines the median
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patients. Speech problems significantly improved more
in responders at the best post-baseline assessment (re-
sponders − 13.25 vs. non-responders − 4.60, p = 0.0027)
and remained better until end of treatment (responders
− 3.38 vs. non-responders + 5.78, p = 0.0154) (Fig. 4g).
Responders and non-responders reported no significant
differences in breathing problems (Fig. 4h). Responders
also evaluated their physical activity and current health
state better than non-responders in the best post-
baseline assessment (Fig. 4i, j).
Time from treatment initiation is also an important
factor. Changes from baseline of the overall VAS score
and the single symptoms are reported in monthly inter-
vals (supplementary Fig. S5). Whereas the overall VAS
score continuously improves during the first three
months in responders, it clearly worsens in non-
responders especially at the third month and later. Espe-
cially swallowing function of mashed food and liquids
slowly improves in responders, whereas it dramatically
worsens in non-responders after three months. Physical
activity remains stable in responders, whereas it worsens
in non-responders already after two months and later.
Association between baseline factors and OS
In the univariate cox regression analysis to study poten-
tially prognostic factors on OS, older age (especially
those between 66 to 75 years), a Charlson score of 0,
lower ECOG scores, female sex, and a less severe overall
VAS score were associated with lower mortality risk
considering all variables with an effect p-value of < 0.2
(Table 2). However, alcohol consumption, body weight,
type of therapy (RT only, CT only, RCT), duration since
initial diagnosis, location of primary tumor (oropharynx,
hypopharynx, larynx, mouth/ lip/ tongue, multiple loca-
tions, other), type of relapse (loco-regional only, any dis-
tant metastases) and smoking status (non-smoker,
former smoker, current smoker) were not associated at a
p-level of 0.2.
In the multivariable analysis only the overall VAS
score remained a prognostic factor for overall sur-
vival, with hazard increase of 12% per 10 points in-
crement for the overall VAS score at baseline. (hazard
ratio: 1.12 per 10 points in VAS, 95% CI 1.05–1.20,
p = 0.0009) (Table 2).
Discussion
The SOCCER trial is a prospective multi-center non-
interventional trial in patients with recurrent and/or
metastatic HNSCC treated with cetuximab-
chemotherapy or cetuximab-radiotherapy combination.
The trial showed a clear association between treatment
response and reduced tumor-related symptoms. How-
ever, in the current era of checkpoint inhibitors the
study endpoint treatment response lost importance. In
the phase III first-line study comparing pembrolizumab
with platinum/5-flurouracil/cetuximab (Keynote-048),
PD-L1 positive patients (combined positive score ≥ 1)
had a significantly higher OS in the pembrolizumab-
arm, despite a much lower response rate of 19% com-
pared to 35% in the EXTREME-arm [4]. Nevertheless,
good palliative treatment should not only prolong sur-
vival, but also improve the patients’ symptoms and con-
sequently their quality of life (QoL). Thus, treatment
regimens with high response rates as chemotherapy may
be more efficient in controlling tumor symptoms than
regimens with low response rates as single agent
Fig. 3 Changes in overall symptom burden in responders and non-responders (ANCOVA analysis). Changes from baseline were analyzed at the
three time points “first post-baseline assessment”, “best post-baseline assessment” and “assessment at treatment end” in responders and non-
responders. Negative values indicate improved symptoms and positive values deteriorated symptoms. n indicates the number of analyzed
questionnaires. Results show the overall VAS score calculated from the ten single symptom VAS scores
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immunotherapiy. Two phase III trials in recurrent and/
or metastatic HNSCC also addressed patients’ QoL using
the EORTC QLQ-C30 and QLQ-H&N35 questionaires.
In the randomized phase III trial comparing nivolumab
with investigators choice in a second line setting (Check-
Mate-141), QoL did not change in the nivolumab arm,
whereas it became worse in the investigators choice arm
[6]. However, the first line platinum/5-flurouracil/cetuxi-
mab combination showed a significant improvement in
QoL in the EXTREME trial [7].
It may be a limitation of the relevance of our results
that an improvement of tumor symptoms is generally
expected after treatment response by experienced clini-
cians. However, the SOCCER trial quantified the effect
of the improvement and displayed the effect on the most
important symptoms. This provides data for clinical de-
cisions, which symptoms may be treated by intense
tumor-directed treatments instead of supportive care
only. Compared to the trials mentioned above, the ques-
tionnaire of the SOCCER trial was study specific and not
evaluated before. Thus, no comparison of the results
with other trials using evaluated quality of life assess-
ments is possible, which is a limitation of the trial. The
questionnaire in the SOCCER trial was designed to
evaluate the effect of treatment response on specific
tumor symptoms in a short questionnaire. As it was not
the aim of the trial to assess quality of life, no informa-
tion was gathered for typical quality of life items as role,
social, emotional or cognitive functioning. As these fac-
tors were not assessed, it can be speculated that found
symptom improvements in responders in the SOCCER
trial might have been biased. Patients who knew they are
responding might have answered symptom questions
more positively. This speculation can be cleared as
tumor symptoms (overall VAS) already significantly im-
proved in the first post baseline assessment, which was
performed long before the first tumor staging procedure.
A unique feature of the current SOCCER trial is the
large multicenter prospective cohort displaying unse-
lected patient data as a relevant number of patients had
ECOG 2 and a Charlson comorbidity index ≥1, who
were not included in the phase III trials mentioned
above. Furthermore, the received rate of pairs of VAS
questionnaires of 67.0% was much higher than in previ-
ous trials, e.g. in the nivolumab second line trial with
only 39% or the EXTREME trial with 44% (regarding
EORTC QLQ-C30) [6, 7]. A limitation of this trial is that
the cohort mainly contains patients treated with cetuxi-
mab in combination with platinum-based chemotherapy,
but also fewer patients treated with radiotherapy and
cetuximab. The overall response rate in this trial was
33%, which is comparable to previously reported 36% of
the EXTREME trial [1]. However, in current phase III
trials with a cisplatin/5-flurouracil/cetuximab in the con-
trol arm the overall response rates might be slightly
higher. This combination achieved an overall response
rate of 36% in the Keynote-048 trial [4] and 40% in the
TPExtreme trial [8].
As mentioned above, treatment response improved
tumor related symptoms in first line treatment with
cetuximab-chemotherapy or cetuximab-radiotherapy
combination. This effect appeared fast, as the improve-
ment was visible in the first post-baseline assessment
scheduled after four weeks. At the end of treatment, most
transiently improved tumor symptoms returned to base-
line in the responders and became worse in the non-
responders, which is probably an effect of tumor progres-
sion. Treatment response improved several different
symptoms of the patients like swallowing of solid food,
mashed food and liquids. The responders also reported
improved senses of smell and taste. Taking into account,
that some of these symptoms might also be caused by
prior surgery and/or chemoradiation [9], patients with
tumor induced symptoms might have even a greater bene-
fit. Especially for these patients with tumor induced swal-
lowing problems, treatment schemes with high response
rates should be preferred. Another obvious improvement
was seen in pain. Systemic treatment schemes with high
response rates might have a superior effect on pain than
only administrating analgesics. Furthermore, responders
also had less speech problems than non-responders. Inter-
estingly, in the EXTREME trial the greatest benefits were
also found in swallowing, pain and speech [7].
These findings are of high relevance for clinical treat-
ment algorithms. As mentioned above, PD-1 inhibitors
changed treatment algorithms in recurrent and/or meta-
static HNSCC as pembrolizumab was approved for first
line treatment either alone or in combination with chemo-
therapy. Most checkpoint-inhibitor trials suggest a clinical
treatment algorithm only based on the PD-L1 status. The
SOCCER trial highlights the relevance of treatment re-
sponse to improve tumor symptom burden, especially
(See figure on previous page.)
Fig. 4 Changes in single tumour symptoms in responders and non-responders (ANCOVA analysis). Changes from baseline were analyzed at the
three time points “first post-baseline assessment”, “best post-baseline assessment” and “assessment at treatment end” in responders and non-
responders. Negative values indicate improved symptoms and positive values deteriorated symptoms. n indicates the number of analyzed
questionnaires. The ten single symptom VAS assessed swallowing of solid food (a), swallowing of mashed food (b), swallowing of liquids (c), pain
(d), restriction of sense of taste (e) and smell (f), speech problems (g), breathing problems (h), restriction of physical activity (i) and the self-
reported current health state (j)
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dysphagia and pain. A clinical consequence of SOCCER
might be to consider treatments with low response rates
as PD-1 inhibitor monotherapy more for patients with
lower symptom burden and and treatment regimens with
higher response rates as chemotherapy-containing combi-
nations for patients with more severe tumor symptom
burden. High response rates of around 36% can be in-
duced by platinum/5-flurouracil either in combination
with cetuximab or pembrolizumab [4] or with the com-
bination of cetuximab and radiotherapy as presented here.
For the cisplatin/docetaxel/cetuximab combination even
response rates up to 46% have been reported [8]. Another
Table 2 Univariate and multivariate Cox proportional hazard models to investigate the association between patient characteristics
and overall survival
Explanatory factors (TAS cohort, N = 391) N Death HR 95% CI p-value
Univariate
Age at study inclusion* ≤ 65 years 241 153 1 –
> 65–75 years 107 60 0.68 0.50–0.92 0.0126
> 75 years 43 28 0.94 0.62–1.38 0.7636
Sex* Male 320 203 1 –
Female 71 38 0.66 0.46–0.92 0.0193
Weight Per 5 kg 391 241 1.02 0.98–1.07 0.3531
Alcohol consumption Never 87 61 1 –
Several times per month 85 51 0.9 0.62–1.30 0.5689
Several times per week or daily 101 60 0.82 0.57–1.17 0.2731
Missing 118 69 0.74 0.52–1.04 0.0836
Smoking habits Never smoked 102 60 1 –
Former smoker 148 94 1.16 0.84–1.61 0.3666
Current smoker 140 86 1.01 0.73–1.41 0.9393
Charlson comorbidity index at study inclusion* 0 188 110 1 –
1 79 57 1.37 0.99–1.87 0.0559
> 1 124 74 1.19 0.88–1.59 0.2545
Chemotherapy/Radiotherapy Radiotherapy only 78 43 1 –
Chemotherapy only 309 195 1.17 0.85–1.64 0.3616
Radio-chemotherapy 4 3 1.82 0.44–5.00 0.3187
Duration since initial diagnosis Per month 391 241 1 1.00–1.00 0.515
ECOG performance status at treatment initiation* 0 65 31 1 –
1 225 145 1.63 1.12–2.45 0.0133
≥ 2 77 53 2.37 1.53–3.73 0.0001
Unknown 24 12 1.5 0.74–2.86 0.2309
Location of primary tumor Oropharynx 93 56 1 –
Hypopharynx 74 45 1.26 0.84–1.86 0.2546
Larynx 42 26 1.25 0.77–1.96 0.3539
Oral cavity 89 59 1.18 0.82–1.71 0.3671
Other 63 35 1.01 0.66–1.53 0.961
Multiple locations 30 20 1.91 1.12–3.14 0.0134
Disease progression at study inclusion Local recurrence only 198 125 1 –
Distant metastases 193 116 0.86 0.66–1.10 0.2276
Overall VAS score* Per 10 points 276 166 1.12 1.05–1.20 0.0009
Multivariatea
Overall VAS score Per 10 points 276 166 1.12 1.05–1.20 0.0009
TAS Target Analysis Set, HR Hazard Ratio, CI Confidence Interval, ECOG Eastern Cooperative Oncology Group, VAS Visual Analogue Scale. aFinal Cox regression
model after backward selection. Within the selection process, all explanatory factors with an effect p-value of < 0.2 in the univariate Cox regression analysis were
considered (*). Only factors with p < 0.05 remained in the final model
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highly effective option for patients with loco-regional re-
lapse can also be reirradiation in combination with cetuxi-
mab [10]. This combination achieved an overall response
rate of 74% in the phase III trial (“Bonner trial”) in
treatment-naive patients and was used in a sub-cohort in
the current SOCCER trial (20% of included patients).
A further finding of this non-interventional study is
that severe tumor symptom burden correlates with re-
duced overall survival. The risk for death increases by
12% per 10 points of the overall VAS score (hazard ratio
1.12). This is not surprising as swallowing problems may
lead to aspiration and subsequent pneumonia or breath-
ing problems may lead to hypoxia. These are potentially
life-threatening situations. This supports the idea to use
platinum-based regimens with higher response rates in
patients with severe tumor symptoms instead of regi-
mens with lower response rates as single agent immuno-
therapy. In patients with loco-regional relapse also
reirradiation in combination with cetuximab should be
considered. Nevertheless, these are intensive treatments
with relevant toxicity. It must be a future aim to develop
treatment regimens with high response rates and low
toxicity especially for palliative situations.
Conclusions
Taken together, in unselected patients beyond random-
ized controlled trials, treatment response lowers tumor
symptom burden in recurrent and/or metastatic HNSC
C. Tumor symptom burden detected by this 10-item
VAS questionnaire was an independent prognostic value
for overall survival.
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